RNA-based gene therapy offers new hope for ALS treatment
A team of researchers have uncovered a previously unknown molecular mechanism that drives the progression of amyotrophic lateral sclerosis (ALS) and succeeded in neutralising it using RNA-based gene therapy.
The study was conducted in the laboratory of Professor Eran Perlson from the Gray Faculty of Medical & Health Sciences and the Sagol School of Neuroscience at Tel Aviv University.
Additional participants included researchers from the Weizmann Institute of Science, Ben-Gurion University of the Negev, and research institutions in France, Turkey, and Italy.
Professor Perlson explained: “We know that in ALS, the neuromuscular junctions – where nerve fibres (axons) meet muscle cells and transmit electrical signals from the brain to the muscles — are disrupted. However, the molecular mechanisms causing this damage remained unknown until now, and consequently no effective treatment has been developed. In this study, we wanted to get to the root of the matter and generate new knowledge that would enable the development of effective drugs for ALS.”
The current study was based on a feature of ALS discovered previously in Professor Perlson’s lab: toxic clusters (aggregates) of a protein called TDP-43 (usually responsible for regulating protein production at the site) form at the tip of the nerve, where it meets the muscle.
Adding microrna-126 rescues neurons
To discover how these TDP-43 aggregates are formed, the researchers used a mouse model for ALS, tissues from ALS patients, and cultures of human stem cells.
The study found that muscle cells produce small RNA molecules called microRNA-126 and send them in vesicles, through the synapsis, to the tip of the nerve cell. The role of these molecules is to prevent the expression of the TDP-43 protein at the neuromuscular junction when it is not needed.
The study further showed that when the amount of microRNA-126 is reduced, a process similar to ALS occurs, and the neurons are destroyed. Conversely, increasing the level of microRNA-126 in tissues taken from ALS patients and in ALS model mice led to a decrease in the levels of TDP-43, and the neurons stopped degenerating and even regenerated.
The researchers concluded that adding microRNA-126 rescues neurons damaged by ALS, prevents degeneration of the neuromuscular junction, and could serve as a basis for developing effective drugs for this currently incurable disease.
Perlson concluded: “In this study, we identified for the first time a critical molecular mechanism of ALS in its early stages: a reduction in the amount of microRNA-126 transferred from muscle to nerve, resulting in the formation of toxic aggregates of the TDP-43 protein that kill neurons. Our findings may serve as a basis for developing an effective gene therapy focused on adding microRNA-126, which could bring hope to millions of patients and their families around the world.”
Diana Turner, Deputy Editor, DDW
